Eyeworld Daily News

2019 ASCRS•ASOA San Diego Daily Tuesday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: http://daily.eyeworld.org/i/1116421

Contents of this Issue

Navigation

Page 1 of 56

ASCRS DAILY NEWS T U E S D AY, M AY 7, 2 019 | A S C R S A S O A A N N U A L M E E T I N G by Liz Hillman EyeWorld Senior Staff Writer R on Kurtz, MD, Aliso Viejo, California, deliv- ered the 2019 Charles D. Kelman Innovator's Lecture, taking attendees through the process of collaborative innovation. Ann Kelman, wife of the late Dr. Kelman, introduced Dr. Kurtz as a "true entrepreneur and collabora- tor extraordinaire." by Liz Hillman EyeWorld Senior Staff Writer Kelman Innovator's Lecture emphasizes importance of collaboration Keeping an eye on innovation Ocular 1 BVI 1 WHEN RELIABILITY COUNTS THE RIGHT PACK MATTERS bvimedical.com Minimize your pack-building time Expedite your OR experience CustomEyes ® your pack BVI, BVI Logo and all other trademarks (unless noted otherwise) are property of Beaver-Visitec International, Inc. ("BVI") © 2019 BVI. 1498237-03 Visit BVI BOOTH 1206 Dextenza ® BIG TIME'I � ION VISIT BOOTH #1737 1 Sawhney AS, �arrett Bassett M, Blizzard C, inventors; Incept, LLC, assignee Drug delivery through hydrogel plugs. US patent 8,409,606 82. April 2, 2013. © 2019 Ocular Therapeutix, Inc. All rights reserved. DEXTENZA is a registered trademark of Ocular Therapeutix, Inc. I PP-US-DX-0097 FOR FULL PRESCRIBING INFORMATION VISIT DEXTENZA.COM M onday's Innovators General Session gave attendees a look at several advances coming down that pike, as well as a little bit of history. continued on page 4 continued on page 3 Patrick Riedel, MD, Min- neapolis, described a new place to shunt aqueous: the ocular surface. The Beacon Aqueous Microshunt (MicroOptix)—the brain child of David Brown, MD, 20 years in development—is 3.1 mm in length with an external flange width of 7 mm. It is implanted into a paracentesis-like incision, allowing aqueous to flow through a central channel. Mitigation against retrograde flow of pathogens would be a concern for such an idea. How- ever, Dr. Riedel said that this is prevented 1) by shear stress and 2) by the polyethylene glycol material that composes the central layer of the three-layer device. Polyeth- ylene glycol is considered the gold standard of anti-biofouling materi- als. It is super hydrophilic, and it prevents adherence of protein and bacteria to the channel wall, Dr. Riedel explained. In a porcine animal model followed to 6 months, Dr. Riedel noted no infections and signifi- cant, persistent IOP lowering. An aggressive bacterial challenge with the device on eight animals did not result in endophthalmitis, Dr. Riedel continued. Preliminary data from an early bird study in the U.S. and E.U. has shown a mean IOP of 13 mm Hg at 6 months, compared to a base- line mean of 27 mm Hg that was medicated with no washout of patients. Eighty-seven percent of Dr. Kurtz takes attendees through the collaborative innovation process.

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld Daily News - 2019 ASCRS•ASOA San Diego Daily Tuesday